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Abstract
The overactive bladder (OAB) is a debilitating condition in which patients suffer from urinary urgency,
frequency and nocturiawith or without urge urinary incontinence. The mainstay of pharmacotherapy for
OAB is muscarinic receptor antagonists, which havebeen shown to be effective treatments for the
symptoms of OAB. The mechanism underlying the efficacy of antimuscarinic agentsagainst the
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muscarinic receptor antagonists may affect bladder signaling via numerous pathways including release
of mediators from the bladder urothelium and activation of suburothelial myofibroblasts and afferent
nerves. Therefore the mucosal cholinergic system may represent another target for the antimuscarinic
agents used to treat OAB.
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The urinary bladder is a largely unappreciated organ.
In normal adults, the urinary bladder performs the
vital functions of storing the body’s liquid waste and
then voiding that waste at a time of our choosing.
During the storage phase, the bladder accommodates
approximately 500 mL of urine with the bladder
wall stretching without any great increase in pressure and without detrusor muscle contractions being
initiated. At full capacity, the afferent nerves lying
within the bladder wall signal fullness to the central
nervous system and at a convenient time voiding is
initiated. During voiding, the pelvic floor muscles
relax, and the detrusor muscle contracts until the
pressure inside the bladder exceeds urethral pressure, at which point voiding occurs. For the majority of individuals, this occurs, about seven or eight
times each day, without any real thought. However
for the approximately 17% of men and women over
the age of 40 years who suffer from an overactive
bladder (OAB) this normal activity of the bladder
is disrupted.1,2 Surprisingly, the disruption of bladder function associated with OAB is more prevalent
than other chronic conditions such as heart disease,
asthma and arthritis.2

with managing symptoms and providing care for
incontinent nursing home residents and costs associated with decreased work productivity. In the US,
the economic costs associated with OAB in the
year 2000 were estimated to be between $12.02 and
$17.5 billion.4 This makes the economic impact of
OAB comparable to the economic impact of influenza, arthritis and osteoarthritis.4
As can be seen from the 2002 definition the cornerstone symptom of OAB is urgency.1,5,6 Urgency is
usually associated with frequency of urination, nocturia and urge urinary incontinence although only
about one third of patients with OAB will experience
incontinence.2,7 In incontinent patients, urodynamic
testing demonstrates detrusor overactivity, where
urine leakage arises from involuntary detrusor contraction.8 The aetiology of these involuntary detrusor
contractions remains unknown.
There are numerous treatment options available for
patients with OAB including biofeedback, electrical
stimulation, bladder training and pharmacotherapy,
either alone or in combination. However, the primary
treatment for the OAB is pharmacotherapy with muscarinic receptor antagonists.9–11

Overview of the Overactive Bladder

Bladder Physiology and the Role
of Muscarinic Receptors

The overactive bladder (OAB) is a debilitating
chronic disorder. In 2002, the International Continence Society defined this condition, in which
patients typically experience symptoms of urgency
(a sudden compelling desire to void that cannot be
deferred), usually with frequency (voiding more
than eight times in 24 hours) and nocturia (being
woken at night with the desire to void), with or
without urge incontinence (the involuntary leakage
of urine associated with urge).3 OAB is a chronic
disease with a major negative influence on quality
of life, especially associated with the limitations it
places on physical and emotional health, vitality and
social functioning.4 The symptoms of OAB affect
all aspects of life including: social (limiting outings due to frequent need to urinate), psychological
(loss of self esteem associated with incontinence),
physical (limitations of physical activities due to
fear of incontinence) and occupational (decreased
productivity).3 OAB can also be associated with
economic costs including the personal costs of managing incontinence, the treatment costs associated
472

The traditional dogma behind the treatment of OAB
with muscarinic receptor antagonists was based on
our understanding of the nerves controlling contraction of the bladder detrusor muscle. During filling,
the bladder detrusor muscle is relaxed, expanding at
low pressure. During voiding the parasympathetic
nerves release acetylcholine onto muscarinic receptors located on the detrusor muscle, causing it to contract.12 Muscarinic antagonists were thought to inhibit
the activation of these detrusor muscarinic receptors
and hence inhibit contraction.
There are five subtypes of muscarinic receptors
(M1–M5) that have been cloned and pharmacologically
characterised.13 Muscarinic receptors are G-protein
coupled receptors. Muscarinic M1, M3 and M5 receptors are coupled to activation of phospholipase C and
IP3 production leading to release of calcium from
intracellular stores.14 In contrast, M2 and M4 receptors
are coupled to inhibition of adenylyl cyclase leading to a decrease in cAMP and to inhibition of calcium-activated potassium channels.14 In the urinary
Clinical Medicine Insights: Therapeutics 2010:2

Antimuscarinics and urinary urgency

b ladder, binding and immunoprecipitation studies15–18
on human detrusor muscle have demonstrated that
the majority of muscarinic receptors are M2 receptor (~70%) with small populations of M3 (~20%) and
M1 (~10%) receptors.18 Functional studies carried out
in M3 knockout mice19 and human detrusor strips20,21
have demonstrated that the small population of M3
receptors are primarily responsible detrusor contraction. Nevertheless, there is some evidence from studies in M2 knockout mice that the large population of
M2 receptors have some functional importance.14,22
M2 receptors enhance the contraction mediated
by M3 receptors and inhibit relaxation via a decrease
in cAMP.23,24
The wall of the bladder also contains a mucosal
layer. The bladder mucosa is made up of the urothelial cell layer, that lines the lumen of the bladder,
and the lamina propria containing blood vessels,
nerves and suburothelial myofibroblasts. The bladder urothelium is a folded transitional epithelium
that expands and unfolds as the bladder volume
increases. The urothelium is made up of large surface
umbrella cells, intermediate cells and basal cells
attached to the basement membrane. Historically,
the urothelial cell layer was considered to be an
inert layer, simply responsible for containing the
urine within the bladder lumen. However, recent
evidence has indicated that the bladder urothelium
has neuronal and sensor properties25 and plays a
role in the regulation of the activity of the underlying nerve and muscle and as such is involved in the
initiation of the micturition reflex.
During bladder filling, stretch of the bladder
wall triggers the release of mediators (such as ATP)
from the urothelium that signal bladder fullness
via the underlying afferent nerves.26 Signals from
these afferent nerves are processed in the brain and,
at an appropriate time, efferent parasympathetic
nerves are activated. The control and integration of
these afferent and efferent signals has been recently
reviewed.27
Within the bladder wall, muscarinic receptors have
not only been identified on the bladder detrusor muscle but have also been localized to the urothelium and
suburothelial myofibroblasts.18,28–32 Radioligand binding studies in both pig32 and human bladder18 have
demonstrated M2 (~70%) and M3 (~30%) muscarinic
receptors in the bladder mucosa. Mucosal muscarinic
Clinical Medicine Insights: Therapeutics 2010:2

mRNA for M1, M2, M3 and M5 receptors have also
been demonstrated using RT-PCR studies.18,29,31
Immunohistochemical studies have localised
muscarinic receptor immunoreactivity to the bladder
urothelium.29–31 Studies in the human31 and mouse
urothelium33 have demonstrated a differential distribution of muscarinic receptor subtypes within the various cell layers of the urothelium (see Fig. 1). While
M2, M3, M4 and M5 receptors were found in all layers
of the urothelium, the M2 receptors were concentrated
in the apical umbrella cell layer and M1 receptors were
found exclusively in the basal cell layer.31,33
Muscarinic M2 and M3 receptors have also been
localised to the suburothelial myofibroblasts.28,30 In
patients with OAB, an increase in both M2 and M3
immunoreactivity on the suburothelial myofibroblasts
was observed.30 Interestingly the increased immunoreactivity correlated with the patients urgency scores30
indicating a possible role for the muscarinic receptors located on the suburothelial myofibroblasts in the
pathophysiology of urgency.

Antimuscarinic Agents Show Clinical
Efficacy against the Symptom
of Urgency

Muscarinic antagonists have been repeatedly shown
to be effective against the symptoms of OAB (for a
systematic review see reference34). However, in contrast to the conventional belief regarding their mechanism of action, recent reports have suggested that
at therapeutic doses muscarinic antagonists do not
inhibit detrusor contractility.11,35 Despite this, these
agents do function to increase bladder capacity and
decrease urgency during bladder filling.35 During
filling there is no activity of the efferent parasympathetic nerves,36,37 hence, while muscarinic antagonists
are effective treatments for OAB their actions cannot be attributed to inhibition of detrusor muscarinic
receptors.
Since OAB was redefined in 2002 a number of
studies have evaluated the effectiveness of antimuscarinic agents against the symptoms associated
with bladder filling, such as micturition frequency
and urgency. Results from a number of these studies
are summarised in Table 1. Studies included in this
table were all 12 week, placebo controlled clinical trials that evaluated the effectiveness of some
of the newer antimuscarinic agents (fesoterodine,
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solifenacin, tolterodine and trospium). The clinical outcomes included were micturition frequency,
urge urinary incontinence and urgency episodes.
These were determined from a three day bladder
diary.
It can be seen from the review by Chapple34 and
the data summarised in Table 1 that treatment with all
of the muscarinic antagonists included (fesoterodine,
solifenacin, tolterodine and trospium) is associated
with some reduction in micturition frequency with a
mean reduction in micturition frequency greater than
14% reported for all of these agents (Table 1). These
antagonists (fesoterodine, solifenacin, tolterodine and
trospium) have also been shown to effectively reduce
urge urinary incontinence (Table 1) with an almost
50% reduction in the number of urge urinary incontinence episodes at the conclusion of the 12 week
clinical trials.
In addition to efficacy against micturition frequency and urge urinary incontinence, these
antagonists have also been seen to reduce the number of urgency episodes per 24 hours (Table 1).
Fesoterodine, tolterodine and trospium inhibit
urgency episodes by approximately 17% while
solifenacin reduces urgency episodes by 59%. The
reasons underlying the improved efficacy of solifenacin against urgency are unknown. While it would
be tempting to postulate that it may be related to the
high degree of M3 receptor selectivity associated
with solifenacin (Table 2), other agents with similar

M3 selectivity (e.g. darifenacin, Table 2) are not
associated with similar reductions in urgency episodes (darifenacin reduces the number of urgency
episodes by 22%).38
In addition to quantifying an effect on the number of urgency episodes, some studies have also
evaluated the efficacy of antimuscarinic agents on
the severity of urgency. Urgency severity has been
evaluated according to PPIUS scale39 in which each
urgency episode is characterised with a score from 0
to 4; with 0 indicating no urgency, 1 mild urgency,
2 moderate urgency, 3 severe urgency and 4 urge
incontinence.39 Using scales such as this, muscarinic
antagonists such as solifenacin,39 darifenacin,40 oxybutynin40 and trospium41 have been shown to reduce
the severity of urgency episodes. Therefore, indicating that muscarinic antagonists not only reduce
micturition frequency and urge urinary incontinence
episodes but also the number and severity of urgency
episodes.
These beneficial effects, on the symptoms of
urgency, raise questions about how urgency is
sensed. Urgency (a sudden compelling desire to
void that cannot be deferred) is a pathological sensation42 that is distinct from the gradual buildup of
sensation that usually accompanies normal bladder filling.6 However, insight into the processes
underlying urgency can be gained from our understanding of the normal bladder sensations during
filling.

Table 1. Efficacy of antimuscarinic agents used to treat OAB against micturition frequency, urge urinary incontinence (UUI)
and urgency episodes.

Micturition frequency
Urge urinary incontinence
Urgency episodes
References

Baseline (Placebo)
Mean % change (Placebo)
Reported significance
Baseline (Placebo)
Mean % change (Placebo)
Reported significance
Baseline (Placebo)
Mean % change (Placebo)
Reported significance

Fesoterodine
(4 mg)

Solifenacin
(5–10 mg)

Tolterodine
(4 mg)

Trospium
(60 mg)

12.2 (12.1)
-14.1 (-8.4)
**
3.9 (3.7)
-47.4 (-28.8)
**
11.7 (11.4)
-17.7 (-8.7)
**

11.3 (11.4)
-20.4 (-11.1)
**
1.9 (2.0)
-84.6 (-45)
**
5.2 (4.7)
-59.1 (-36.2)
***

11.9 (12)
-17.8 (-8.1)
**
3.7 (3.7)
-49.5 (-30.3)
*
9.2 (11.4)
-16.4 (-9.6)
*

12.8 (12.8)
-20.5 (-13.8)
***
4.0 (4.1)
-59.5 (-43.6)
***
11.3 (9.6)
-20.4 (-9.6)
***

84–86

39,87–89

85,86,89

41,90–92

Notes: Reported significance *P , 0.05, **P , 0.001, ***P , 0.0001.
Definitions: Micturition frequency is defined as the number of times a patient passed urine (including incontinence episodes) in a 24 hour period. Urge
urinary incontinence (UUI) is defined as the number of times the patient experiences involuntary leakage of urine accompanied by or immediately
preceded by urgency in a 24 hour period. Urgency episodes are defined as the number of times a patient recorded an urgency episode with or without
incontinence in a 24 hour period.
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Muscarinic Involvement in Afferent
Processes in the Bladder Mucosa

It is believed that filling sensations from the bladder are mediated by afferent nerves located in the
lamina propria of the mucosa. These afferent nerves
(Aδ and C fibres) are closely associated with both the
urothelium and the underlying layer of suburothelial
myofibroblasts.43,44 These nerve fibres are activated by
stretch and chemical stimuli45,46 with the myelinated
Aδ fibres thought to be associated with normal micturition processes while the unmyelinated C fibres are
thought to be responsible for sensations arising from
painful stimuli.45–47
During filling, stretch of the bladder wall is
associated with release of mediators from the
urothelium.26,48–52 Some of these mediators, such
as ATP26 are thought to stimulate the underlying
afferent nerves while others, such as nitric oxide
(NO)53,54 are thought to be inhibitory.55,56 These
mediators (ATP, NO) are therefore involved in the
transduction of stretch of the bladder wall during
filling, into activation of sensory afferent fibres.55,56
We have recently reported that the concentration of
ATP in voided urodynamic fluid correlated significantly with voided volume in normal and overactive bladders49 suggesting that stretch of the bladder
wall during filling leads to an incremental release
of ATP from the urothelium. ATP can then activate
the underlying afferent nerves, with increased afferent nerve firing associated with bladder filling.57
Afferent nerve activation occurs via ligand-gated
P2X3 receptors.45,51,58 In knockout mice, loss of P2X3
receptors leads to decreased voiding frequency and
increased bladder capacity.58
In addition to activating the afferent nerves, ATP
released from the urothelium can also activate purinergic receptors located on suburothelial myofibroblasts. These purinergic receptors may be either
Table 2. Reported affinity for antimuscarinic agents
against human muscarinic receptors expressed in Chinese
Hamster Ovary cells (data summarized from93).
Fesoterodine
Darifenacin
Tolterodine
Solifenacin
Trospium

M1

M2

M3

M4

M5

15.9
65.8
15.9
83.9
3.5

2.5
116
10.1
93.5
1.1

46.4
3.7
5.5
19.3
1.2

10.4
33.1
2.7
18.5
1.4

1.5
24.2
2.4
35.0
6.1

Clinical Medicine Insights: Therapeutics 2010:2

ligand-gated P2X receptors59 or G-protein coupled,
P2Y receptors.60 Suburothelial myofibroblasts are
closely associated with the afferent nerves of the
lamina propria61,62 and may function to modulate and
amplify the afferent nerve responses following stretch
of the bladder wall.43,63
Stretch of the bladder wall has also been
associated with release of acetylcholine.37,52,64 Acetylcholine release is not sensitive to the nerve toxin
tetrodotoxin and is dependent on the presence of
the urothelium, suggesting that the urothelium is a
source of non-neuronal acetylcholine.37 The urothelium has been shown to contain the cellular machinery required for the synthesis of acetylcholine,
including choline acetyltransferase52 and carnitine
acetyltransferase.56,57,65,66 Acetylcholine is therefore
another stimulatory agent released from the bladder
urothelium.
Recent studies have demonstrated that antimuscarinic agents such as oxybutynin have an inhibitory effect on afferent nerve firing.56,57,66 Systemic
administration of oxybutynin and darifenacin signi
ficantly decreased the firing rate of both Aδ and C
fibres during bladder filling.57,66 Similarly, long-term
administration of oxybutynin led to an increase in
the micturition interval and increased bladder capacity together with decreased c-Fos expression in the
spinal cord, which is associated with decreased
activity of afferent nerves.67 In contrast, intravesical administration of muscarinic agonists, carbachol
and oxotremorine, leads to increased excitability of
bladder afferents, as seen by a decrease in the intercontraction interval.54,68,69 Although, instillation of
low concentrations of oxotremorine was also associated with an inhibitory effect on bladder afferents
mediated by NO.54
Stimulation of the bladder mucosa by the muscarinic agonist carbachol also leads to the release of an as
yet unidentified “urothelial derived inhibitory factor”
(UDIF).32,70,71 Release of UDIF is mediated via activation of muscarinic M2 receptors.72 UDIF released following activation of muscarinic receptors functions
to directly inhibit detrusor muscle contractions. This
effect can be observed in an organ bath and hence is
independent of any stimulatory or inhibitory effects of
muscarinic agonists on bladder afferent nerve fibres.
The mechanism underlying the effect of antimuscarinic agents on afferent nerve function remains
475
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Mucosal Muscarinic Receptors
as Therapeutic Targets

uncertain, however it is likely to involve mucosal
muscarinic receptors.18,28–32 A possible mechanism
is summarised in Figure 1. Acetylcholine released
from the urothelium in response to stretch52,64 could
act in an autocrine or paracrine manner to stimulate
urothelial muscarinic receptors and trigger the release
of ATP.50 The ATP released may then facilitate the
generation of afferent nerve activity either directly,
via P2X3 receptors, or indirectly via activation of
purinergic receptors on located the suburothelial
myofibroblasts. In addition, acetylcholine could also
activate the muscarinic receptors located on the suburothelial myofibroblasts.28,30

Mucosal muscarinic receptors may therefore represent
another target for antimuscarinic therapy. Following
oral administration, antimuscarinic agents may gain
access to mucosal muscarinic receptors via the bloodstream. In addition, any antimuscarinic agent excreted
in the urine unchanged, or as an active metabolite,
may have direct access to urothelial muscarinic receptors.73 In vivo studies in rat bladder have suggested that
antimuscarinic agents excreted in the urine may have
therapeutic potential. In order to examine this, human
volunteers were administered antimuscarinic agents

M2
<<Stretch>>

ACh
UDIF

ACh
M2

M3

M4

M5

Urothelium

M1
P2X3

ACh

ATP
P2X

M3

Myofibroblasts

M2
P2Y

Afferent nerve

Detrusor muscle
M2 M3

ACh

Efferent nerve
M2 M 3

Figure 1. Possible mechanism for cholinergic signaling in bladder activity. During filling stretch of the bladder wall induces release of acetylcholine (and
ATP) from urothelial cells. This acetylcholine may then activate urothelial muscarinic receptors which stimulates further release of ATP. Both acetylcholine
and ATP may activate the suburothelial myofibroblasts via muscarinic or purinergic receptors which may in turn alter the activity of the associated afferent
nerves. ATP can also activate afferent nerves directly via P2X3 receptors. This afferent nerve activity can then signal bladder fullness to the central nervous
system which in turn activates the parasympathetic efferent nerves to release acetylcholine onto muscarinic receptors located on the detrusor smooth
muscle leading to bladder contraction and voiding.
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(darifenacin, oxybutynin, solifenacin, tolterodine and
trospium) at the regularly prescribed dose for 5 days.
Samples of urine from these volunteers was then
instilled into rat bladders and the effect on carbacholinduced detrusor overactivity monitored.68,69,74
Intravesical administration of urine from volunteers who took trospium prevented the reduction in
bladder capacity and inter-contraction interval (detrusor overactivity) induced by carbachol.68,69 Similarly,
urine from volunteers who took solifenacin was able
to prevent carbachol-induced detrusor overactivity.74
However, urine from volunteers who took oxybutynin,68,69 tolterodine68,69 or darifenacin74 was unable
to inhibit carbachol-induced detrusor overactivity. In
all of these studies68,69,74 the urine was only instilled
into the bladder for a short period of time in order
to minimise any absorption across the mucosal wall
and hence to remove any direct effects on the detrusor
muscle itself.
Trospium and solifenacin are unusual in that pharmacokinetic studies have shown that a relatively high
percentage of the administered dose is excreted in the
urine unchanged (Table 3). It can therefore be concluded that the ability of some of the antimuscarinic
agents to prevent carbachol-induced detrusor overactivity is determined by the actions of the unchanged
drug and/or active metabolite excreted in urine.73
Interestingly, in clinical trials these two agents (trospium and solifenacin) have been associated with the
highest percentage reduction of the number of urgency
episodes in a 24 hour period (20.4% and 59.1%
respectively, see Table 1). However, urinary excretion of parent compound or active metabolite is not
the only requirement for clinical efficacy. Darifenacin also reduces the number of urgency episodes by
a similar percentage38 although urine from volunteers
taking darifenacin was unable to prevent carbacholinduced detrusor overactivity74 and this agent is not
excreted via the urine (Table 3).

Current use of muscarinic receptor antagonists is
limited by side effects such as dry mouth and constipation, that are associated with the binding of these
agents to muscarinic receptors located in the salivary
glands75 and gastrointestinal tract.76,77 These side
effects result in many patients discontinuing therapy3 and may in part explain why long term clinical
improvement is only seen in 35% of patients.78 These
side effects occur due to a lack of organ selectivity
of antimuscarinic agents.79 In the future, improvements in the bladder selectivity of muscarinic receptor antagonists may be achieved by developing
muscarinic receptor antagonists that are targeted to
the bladder mucosa via excretion in the urine or via
intravesical administration. Some clinical efficacy
has previously been obtained from intravesical instillation of oxybutynin in patients with OAB.80–82 In
rats, intravesical administration of oxybutynin was
associated with greater bladder selectivity83 and as
discussed above reduces stretch activated afferent
nerve firing56,57,66 which may be associated with urinary urgency.

Conclusions

Over the last 15 years, antimuscarinic agents have
been shown to be effective treatments for the
symptoms of OAB including micturition frequency,
urge urinary incontinence and urgency episodes.
Previously this therapy was thought to target the
muscarinic receptors located on the detrusor muscle,
however, recent research indicates that this is not the
case. The mechanism underlying the clinical efficacy of antimuscarinic agents against the symptoms
of OAB is not completely understood. This efficacy
is likely to involve interplay between the muscarinic
receptors located in the bladder mucosa and mediators released from the bladder urothelium, including
ATP and acetylcholine Figure 1. ATP and acetylcholine released from the urothelium may act on the

Table 3. Urinary excretion of antimuscarinic agents.
% excreted in urine
% excreted unchanged
% excreted as an active
metabolite
References

Darifenacin

Oxybutynin

Solifenacin

Tolterodine

Trospium

3%

,5%

69%
15%

77%
2.4%
14%

6%
60%

94

95

96

97

95
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suburothelial myofibroblasts and associated afferent
nerves to mediate the sensations of bladder filling.
Thus, the cholinergic system is integral to bladder
afferent signaling and as such muscarinic receptor
antagonists may affect bladder signaling via numerous pathways.
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